ArticleDrug, healthcare and patient safety2010
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management.
Article in Drug, healthcare and patient safety, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02972138 (Vitamin D Supplementation and Anti-resorptive Therapy), which is not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Vitamin D Supplementation and Anti-resorptive Therapy (Bisphosphonates) Treatment of Young Adult Patients With Sickle Cell Disease
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Food-derived extracellular vesicles for treatment of osteoporosis: a systematic review and meta-analysis of preclinical animal studies.European journal of medical research · 2025Pooled it
- Evaluation of Safety and Dosimetry ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study.Journal of bone and mineral metabolism · 2020Trial
- Efficacy of zoledronic acid for chronic low back pain associated with Modic changes in magnetic resonance imaging.BMC musculoskeletal disorders · 2014Trial
- Paget's Disease Unveiled in a Primary Care Setting: A Case of High Alkaline Phosphatase.Cureus · 2026Article
- Effects of hydroxybisphosphonates-conjugated sitafloxacin on fracture healing and skeletal growth in mice.JBMR plus · 2026Article
- Quercetin in bone regeneration: optimization of drug delivery system and study of its synergistic mechanism with bone tissue engineering.Frontiers in pharmacology · 2026Review
- Exosomes from young plasma stimulate the osteogenic differentiation and prevent osteoporosis via miR-142-5p.Bioactive materials · 2025Article
- Bisphosphonate Use in Acute Spinal Cord Injury: A Focused Systematic Review on Zoledronic Acid.Cureus · 2025Review
- Adaptation of mitochondrial bioenergetics to coenzyme Q deficiency in human endothelial cells after chronic exposure to bisphosphonates.Scientific reports · 2025Article
- Article
- Spectrum of activity and mechanisms of azole-bisphosphonate synergy in pathogenicMicrobiology spectrum · 2024Article
- Biodistribution and dosimetry ofEJNMMI research · 2024Article
- The bisphosphonates alendronate and zoledronate induce adaptations of aerobic metabolism in permanent human endothelial cells.Scientific reports · 2023Article
- Article
- Review
- Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.Frontiers in immunology · 2021Article
- May zoledronic acid have negative effects on cognition and muscle performance?Irish journal of medical science · 2020Article
- Ionic Diffusion and Drug Release Behavior of Core-Shell-Functionalized Alginate-Chitosan-Based Hydrogel.ACS omega · 2020Article
- Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways.International journal of molecular medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphosphonates (BPs) are widely used in the treatment of postmenopausal osteoporosis and other metabolic bone diseases. They bind strongly to bone matrix and reduce bone loss through inhibition of osteoclast activity. They are classified as nitrogen- and non-nitrogen-containing bisphosphonates (NBPs and NNBPs, respectively). The former inhibit farnesyl diphosphate synthase while the latter induce the production of toxic analogs of adenosine triphosphate. These mechanisms of action are associated with different antifracture efficacy, and NBPs show the most powerful action. Moreover, recent evidence indicates that NBPs can also stimulate osteoblast activity and differentiation. Several randomized control trials have demonstrated that NBPs significantly improve bone mineral density, suppress bone turnover, and reduce the incidence of both vertebral and nonvertebral fragility fractures. Although they are generally considered safe, some side effects are reported (esophagitis, acute phase reaction, hypocalcemia, uveitis), and compliance with therapy is often inadequate. In particular, gastrointestinal discomfort is frequent with the older daily oral administrations and is responsible for a high proportion of discontinuation. The most recent weekly and monthly formulations, and in particular the yearly infusion of zoledronate, significantly improve persistence with treatment, and optimize clinical, densitometric, and antifracture outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.